Home › Compare › VLON vs SBUX

VLON vs SBUX: Dividend Comparison 2026

VLON yields 500.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VLON wins by $61399.36M in total portfolio value
10 years
VLON
VLON
● Live price
500.00%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61399.52M
Annual income
$44,063,578,515.70
Full VLON calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — VLON vs SBUX

📍 VLON pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVLONSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VLON + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VLON pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VLON
Annual income on $10K today (after 15% tax)
$42,500.00/yr
After 10yr DRIP, annual income (after tax)
$37,454,041,738.34/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, VLON beats the other by $37,453,981,272.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VLON + SBUX for your $10,000?

VLON: 50%SBUX: 50%
100% SBUX50/50100% VLON
Portfolio after 10yr
$30699.85M
Annual income
$22,031,824,826.08/yr
Blended yield
71.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

VLON
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
36.7
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VLON buys
0
SBUX buys
0
No recent congressional trades found for VLON or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVLONSBUX
Forward yield500.00% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$61399.52M ✓$167.0K
Annual income after 10y$44,063,578,515.70 ✓$71,136.45
Total dividends collected$59892.67M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: VLON vs SBUX ($10,000, DRIP)

YearVLON PortfolioVLON Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$60,700$50,000.00$11,121$420.68+$49.6K → VLON
2$348,594$283,644.86$12,548$648.40+$336.0K → VLON
3$1,895,372$1,522,376.89$14,440$1,013.98+$1.88M → VLON
4$9,763,990$7,735,942.00$17,068$1,617.30+$9.75M → VLON
5$47,691,977$37,244,507.54$20,912$2,649.52+$47.67M → VLON
6$221,049,019$170,018,603.23$26,875$4,499.29+$221.02M → VLON
7$972,993,924$736,471,474.07$36,771$8,014.12+$972.96M → VLON
8$4,070,762,075$3,029,658,575.98$54,542$15,197.11+$4070.71M → VLON
9$16,201,818,371$11,846,102,950.68$89,602$31,242.49+$16201.73M → VLON
10$61,399,524,173$44,063,578,515.70$167,011$71,136.45+$61399.36M → VLON

VLON vs SBUX: Complete Analysis 2026

VLON — Stock

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Full VLON Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this VLON vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VLON vs SCHDVLON vs JEPIVLON vs OVLON vs KOVLON vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.